• Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial 

      Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2019)
      Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ...
    • Plasma methylmalonic acid predicts risk of acute myocardial infarction and mortality in patients with coronary heart disease: A prospective 2-cohort study 

      Dhar, Indu; Lysne, Vegard; Ulvik, Arve; Svingen, Gard Frodahl Tveitevåg; Pedersen, Eva Kristine Ringdal; Bjørnestad, Espen Øglænd; Olsen, Thomas; Borsholm, Robert Andre; Laupsa-Borge, Johnny; Ueland, Per Magne; Tell, Grethe Seppola; Berge, Rolf Kristian; Mellgren, Gunnar; Bønaa, Kaare Harald; Nygård, Ottar Kjell (Peer reviewed; Journal article, 2023)
      Background Elevated plasma methylmalonic acid (MMA) is reported in patients with established coronary heart disease (CHD) and is considered a marker of vitamin B12 deficiency. Moreover, MMA-dependent reactions have been ...
    • Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations 

      Vestad, Beate; Ueland, Thor; Lerum, Tøri Vigeland; Dahl, Tuva Børresdatter; Holm, Kristian; Barratt-Due, Andreas; Kåsine, Trine; Dyrhol-Riise, Anne Ma; Stiksrud, Birgitte; Tonby, Kristian; Hoel, Hedda; Olsen, Inge Christoffer; Henriksen, Katerina N.; Tveita, Anders Aune; Manotheepan, Ravinea; Haugli, Mette; Eiken, Ragnhild; Berg, Åse; Halvorsen, Bente; Lekva, Tove; Ranheim, Trine; Michelsen, Annika Elisabeth; Kildal, Anders Benjamin; Johannessen, Asgeir; Thoresen, Lars; Skudal, Hilde Kristin; Kittang, Bård Reiakvam; Olsen, Roy Bjørkholt; Ystrøm, Carl Magnus; Skei, Nina Vibeche; Hannula, Raisa; Aballi, Saad; Kvåle, Reidar; Skjønsberg, Ole Henning; Aukrust, Pål; Hov, Johannes Espolin Roksund; Trøseid, Marius (Peer reviewed; Journal article, 2022)
      Background - Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, with gut barrier dysfunction and gut ...
    • Vascular risk factor control and adherence to secondary preventive medication after ischemic stroke 

      Gynnild, Mari Nordbø; Aakerøy, Rachel; Spigset, Olav; Askim, Torunn; Beyer, Mona Kristiansen; Ihle-Hansen, Hege; Munthe-Kaas, Ragnhild; Knapskog, Anne Brita; Lydersen, Stian; Næss, Halvor; Røsstad, Tove Garåsen; Seljeseth, Yngve Müller; Thingstad, Pernille; Saltvedt, Ingvild; Ellekjær, Hanne (Peer reviewed; Journal article, 2020)
      Background Studies regarding adequacy of secondary stroke prevention are limited. We report medication adherence, risk factor control and factors influencing vascular risk profile following ischaemic stroke. Methods A ...